Psychedelic therapy aims to break the relapse cycle in alcoholism and depression
NCT ID NCT07638553
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This phase 3 trial investigates whether high-dose psilocybin, given alongside psychotherapy, can prevent relapse in people with severe alcohol use disorder who also have depressive symptoms. Participants receive either a high dose (25 mg) or a low dose (3 mg) of psilocybin in two sessions three weeks apart. The study measures relapse rates and time to relapse over six months, building on promising pilot results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin
What this could lead to
If successful, this could offer a new, fast-acting treatment option for people with both alcohol use disorder and depression, helping them stay sober longer.
What could go wrong
This is a phase 3 trial, but results may not apply to everyone. Psilocybin can cause intense psychological effects, and the therapy requires careful supervision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH Le Vinatier
NOT_YET_RECRUITINGBron, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Besançon
NOT_YET_RECRUITINGBesançon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Brest
NOT_YET_RECRUITINGBrest, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Saint-Etienne
NOT_YET_RECRUITINGSaint-Priest, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Bordeaux
NOT_YET_RECRUITINGBordeaux, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Nantes
NOT_YET_RECRUITINGNantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Nîmes
RECRUITINGNîmes, 30029, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Hospitalier de la Côte Basque
NOT_YET_RECRUITINGBayonne, France
Contact Phone: •••-•••-•••• Email: •••••@•••••